You have successfully logged out.
Randomized controlled trial for de-novo
First in Man Trials in Malaysia
Ahmad WAW et al. Cardiovascular Interventions 15.7 (2022): 770-779.
|PCB (n=35)||SCB (n=35)||P value|
|Unscheduled angiography||2 (6)||3 (9)||1.000|
No difference in clinical endpoints after 12 months.
Not any event of TLR, Stent thrombosis, TV-MI.
This first-in-human comparison of a novel SCB with a crystalline coating showed similar angiographic outcomes in the treatment of coronary de novo disease compared with a clinically proven PCB. However, late luminal enlargement was more frequently observed after PCB treatment.